Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 4/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 5/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30388939 | 1.00 | NCF1 (0.51) | NCF1AGTR1AGTR2PARP1PDE4A | |
| SCHEMBL88762 | 0.84 | NCF1 (0.52) | NCF1AGTR1AGTR2 | |
| SCHEMBL30388617 | 0.83 | NCF1 (0.51) | NCF1AGTR1AGTR2PDE4APDE4B | |
| SCHEMBL5538132 | 0.79 | KDM4E (0.51) | NCF1AGTR1AGTR2 | |
| SCHEMBL10677788 | 0.79 | ACP1 (0.62) | NCF1 | |
| SCHEMBL29531776 | 0.79 | NCF1 (0.44) | NCF1AGTR1AGTR2 | |
| SCHEMBL89580 | 0.78 | NCF1 (0.49) | NCF1PDE4APDE4BPDE3BPDE3A | |
| SCHEMBL31425610 | 0.78 | NCF1 (0.49) | NCF1PARP1PDE4APDE4BPDE3B | |
| SCHEMBL8290938 | 0.77 | LMNA (0.58) | AGTR1AGTR2PDE4APDE4BPDE3B | |
| SCHEMBL13168773 | 0.77 | PDE4A (0.42) | NCF1AGTR1AGTR2PARP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459921-B2 | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-04 | — | — | US | disclosed |
| CN-114085212-B | Isoindoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-05-02 | — | — | CN | disclosed |
| CN-114085212-A | Isoindoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-02-25 | — | — | CN | disclosed |
| US-20220041576-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-02-10 | — | — | US | disclosed |
| CN-110963994-B | Isoindoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-02-08 | — | — | CN | disclosed |
| EP-3862348-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-08-11 | — | — | EP | disclosed |
| CN-110963994-A | Isoindoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2020-04-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459921-B2 | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | CUL4B, CUL4A, UBQLN1 | NCF1 2631/4885AGTR1 2173/4885AGTR2 2503/4885 |
| US-20220041576-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CUL4B, CUL4A, UBQLN1 | NCF1 2631/4885AGTR1 2173/4885AGTR2 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.